October 25, 2012

Q3 2012 Business EPS1 reflects patent expirations Growth Platforms2 reached over 70% of sales

 

Q3 2012 Business EPS1 reflects patent expirations Growth Platforms2 reached over 70% of sales

Commenting on the Group’s performance in Q3 2012, Sanofi Chief Executive Officer, Christopher A. Viehbacher said, “The loss of exclusivity for Eloxatin® in August in the U.S. marks the final step in the genericization of our legacy blockbusters. The solid performance of our growth platforms2 which account for over 70% of sales, coupled with tight cost control, allowed us to limit the impact of the patent cliff on business EPS1 this quarter. Furthermore, we continue to make progress with our pipeline with the launch of Zaltrap® and Aubagio® in the U.S. and the FDA approval for Auvi-QTM ”.